Is GNCA A Good Stock To Buy Now?
A whopping number of 13F filings filed with U.S.
Genocea Biosciences Inc. (GNCA)
Get Email AlertsHedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 5,084,184 | $6,355 | 0.11% | |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 4,012,404 | $5,016 | 0.2% | |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 3,079,756 | $3,850 | 0.85% | |
| 4. | Point72 Asset Management Steve Cohen | 2,576,385 | $3,220 | -3% | 0.01% |
| 5. | Kingdon Capital Mark Kingdon | 1,972,056 | $2,465 | 0.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.06 | 4,760 | Officer, Director | 4,760 | 2020-11-10 | Filing | |
| $2.25 | 1,260,504 | Large Shareholder | 4,626,389 | 2020-07-24 | Filing | |
| $2.25 | 3,151,260 | Large Shareholder | 10,376,936 | 2020-07-24 | Filing | |
| $2.25 | 3,151,260 | Large Shareholder | 10,376,936 | 2020-07-24 | Filing | |
| $2.25 | 3,151,260 | Large Shareholder | 10,376,936 | 2020-07-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.09 | 2,500 | Officer | 43,750 | 2022-05-25 | Filing | |
| $0.09 | 16,525 | Officer | 90,605 | 2022-05-25 | Filing | |
| $0.08 | 24,407 | Officer | 76,743 | 2022-05-26 | Filing | |
| $1.25 | 1,212 | Officer | 96,193 | 2022-04-04 | Filing | |
| $1.25 | 963 | Officer | 91,775 | 2022-04-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 10,376,936 | $12,971 | 0.37% | |
| 2. | 1,574,979 | $1,969 | 0% | |
| 3. | 1,134,453 | $1,418 | 0.07% | |
| 4. | 375,000 | $469 | 32.05% | |
| 5. | 291,733 | $364 | 0% |
News See All
Genocea Biosciences Inc (GNCA): Are Hedge Funds Right About This Stock?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Genocea Biosciences Inc (GNCA): Hedge Fund Sentiment Unchanged
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
How Genocea Biosciences Inc (GNCA) Stacks Up Against Its Peers
There are several ways to beat the market, and investing in small cap stocks has historically been one of them.
GNC Deal Could Be In Jeopardy, Genocea Taming Herpes, Opexa Not Taming MS, Plus The Latest on Theravance
The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) has gained 0.21% this morning, in lockstep with the S&P 500, as it is wont to do.
Valeant, Morgan Stanley, Genocea: Stocks In The Spotlight For The Wrong Reasons Today
It's Monday and shareholders of Morgan Stanley (NYSE:MS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Genocea Biosciences Inc (NASDAQ:GNCA) are certainly on alert as the value of their shares ...
Alere Inc (ALR), Lion Biotech (LBIO), Genocea Biosciences Inc (GNCA), Advaxis Inc (ADXS) Among Broadfin’s Top New Health Picks
Broadfin Capital, LLC is a New York-based hedge fund, whose $1.28-billion equity portfolio is invested in healthcare companies.
Billionaire Hedge Funds
